CD48 as a Novel Target in Asthma Therapy

Author(s): Ariel Munitz, Ido Bachelet, Francesca Levi-Schaffer

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 1 , Issue 1 , 2007

Become EABM
Become Reviewer


CD48, a CD2-related surface molecule, emerges as a critical effector molecule in immune responses. CD48 has a striking array of biological functions, among them adhesion, pathogen recognition, cellular activation, and cytokine regulation. Still, it is surprising that this mysterious molecule has not yet met its proper use as a therpeutical target in exaggerated immune disorders like hematopoietic tumors, autoimmunity and allergic reactions. Recently, CD48 was investigated in our laboratory as an effector molecule in human eosinophil function and in asthma. In this review, we shall discuss the known aspects of CD48 biology and describe the recent advances regarding the role of CD48 in human disease. Moreover, we shall review inventions making use of CD48, and discuss recent patents and the potential of CD48 as a future target for the therapy of allergic and other diseases.

Keywords: CD48, asthma, immunotherapy, mast cells, eosinophils, cancer, marker, 2B4, CD2, phagocytosis

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [9 - 12]
Pages: 4
DOI: 10.2174/187221307779815057

Article Metrics

PDF: 21